Literature DB >> 25635013

Draft Genome Sequences of Four Vibrio parahaemolyticus Isolates from Clinical Cases in Canada.

Swapan Banerjee1, Nicholas Petronella2, Courtney Chew Leung3, Jeffrey Farber3.   

Abstract

Vibrio parahaemolyticus is a leading cause of bacterial gastroenteritis following ingestion of contaminated seafood. This report presents the draft genome sequences of four clinical strains of V. parahaemolyticus isolated in Canada. All four strains lack traditional pathogenic markers and possess uniquely individual characteristics identified using other typing criteria.
Copyright © 2015 Banerjee et al.

Entities:  

Year:  2015        PMID: 25635013      PMCID: PMC4319507          DOI: 10.1128/genomeA.01482-14

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Vibrio parahaemolyticus is a halophilic bacterium associated with plankton and seafood harvested from estuaries around the world. Some strains of V. parahaemolyticus are pathogenic and cause seafood-borne illnesses (1, 2). Pathogenicity is determined by confirming the presence of thermostable direct hemolysin (TDH) and TDH-related hemolysin (TRH) encoded by tdh and trh, respectively (1, 3, 4). The majority of clinical isolates test positive for one or both of these hemolysin genes by PCR. However, isolates lacking both tdh and trh markers have been detected in patients and reported in recent years from Canada (5) as well as from the United States (6). Here, we report the draft genomic sequences of four V. parahaemolyticus clinical isolates that lack the known virulence markers (tdh− trh−). The strains were found to be diverse in terms of genotypic characteristics and geographic location (5). Genome sequences of V. parahaemolyticus strains, RIMD 2210633, tdh+ trh− (7), and AQ4037, tdh− trh+ (8), have been reported earlier and used as references for comparative analysis. Short-read sequence data for the V. parahaemolyticus isolates were generated using a HiSeq Benchtop sequencer (Illumina, San Diego) for 500 cycles. Sequence data were assembled as described earlier (9, 10). The number of reads generated was 5,518,100 for strain T12739, 6,752,516 for T9109, 7,207,234 for 09-5357, and 3,732,814 for 04-2548. Reads were assembled de novo into high-quality draft genomes with SPAdes v3.1.1 (11, 12), resulting in 55 nonoverlapping contiguous sequences (contigs) with a total length of 5,114,934 bases, 45.29% G+C content, and 108-fold coverage for T12739. The assembly of T9109 resulted in 63 non-overlapping contigs with a total length of 5,082,583 bases, 45.30% G+C content, and 133-fold coverage. In addition, 09-5357 was assembled into 49 nonoverlapping contigs with a total length of 5,297,642 bases, 45.27% G+C content, and 136-fold coverage. Lastly, 04-2548 was assembled into 101 nonoverlapping contigs with a total length of 5,549,224 bases, 45.05% G+C content, and 68-fold coverage. All four V. parahaemolyticus isolates tested positive by PCR for the presence of thermolabile hemolysin (tlh). Sequence comparison with the reference strains confirmed the absence of the known virulence markers (tdh, trh) in all four isolates. Preliminary sequence analysis targeting the two type III secretion systems (T3SSs) indicated the presence of the 11 core T3SS-1 related genes in all four isolates. In addition, the presence of transcriptional regulator opaR (VP2516) and adhesion factor mam7 (VP1611) were confirmed in all four strains, providing evidence of some regulatory and host cell attachment functions (13). However, the sequences of 12 core proteins of T3SS-2 were not detected in any of the isolates reported here, suggesting that the complete virulence mechanism of these strains will require continued investigation.

Nucleotide sequence accession numbers.

These whole-genome shotgun studies have been deposited at DDBL/EMBL/GenBank under accession numbers JTGS00000000 (04-2548), JTGQ00000000 (T12739), JTGR00000000 (T9109), and JTGT00000000 (09-5357). The first versions described in this announcement are JTGS01000000, JTGQ01000000, JTGR01000000, and JTGT01000000, respectively.
  13 in total

1.  Biochemical, serological, and virulence characterization of clinical and oyster Vibrio parahaemolyticus isolates.

Authors:  Jessica L Jones; Catharina H M Lüdeke; John C Bowers; Nancy Garrett; Markus Fischer; Michele B Parsons; Cheryl A Bopp; Angelo DePaola
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

2.  Phenotypic and genotypic characterization of Canadian clinical isolates of Vibrio parahaemolyticus collected from 2000 to 2009.

Authors:  Swapan K Banerjee; Ashley K Kearney; Celine A Nadon; Christy-Lynn Peterson; Kevin Tyler; Laurene Bakouche; Clifford G Clark; Linda Hoang; Matthew W Gilmour; Jeffrey M Farber
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 3.  Virulence determinants for Vibrio parahaemolyticus infection.

Authors:  Lingling Zhang; Kim Orth
Journal:  Curr Opin Microbiol       Date:  2013-02-22       Impact factor: 7.934

4.  Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell.

Authors:  J Glenn Morris
Journal:  Clin Infect Dis       Date:  2003-07-03       Impact factor: 9.079

5.  BayesHammer: Bayesian clustering for error correction in single-cell sequencing.

Authors:  Sergey I Nikolenko; Anton I Korobeynikov; Max A Alekseyev
Journal:  BMC Genomics       Date:  2013-01-21       Impact factor: 3.969

6.  Enterotoxigenicity of Vibrio parahaemolyticus with and without genes encoding thermostable direct hemolysin.

Authors:  M Nishibuchi; A Fasano; R G Russell; J B Kaper
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

7.  Purification and characterization of a hemolysin produced by a clinical isolate of Kanagawa phenomenon-negative Vibrio parahaemolyticus and related to the thermostable direct hemolysin.

Authors:  T Honda; Y X Ni; T Miwatani
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

8.  Comparative genomic analysis of Vibrio parahaemolyticus: serotype conversion and virulence.

Authors:  Yuansha Chen; O Colin Stine; Jonathan H Badger; Ana I Gil; G Balakrish Nair; Mitsuaki Nishibuchi; Derrick E Fouts
Journal:  BMC Genomics       Date:  2011-06-06       Impact factor: 3.969

Review 9.  Distribution and dynamics of epidemic and pandemic Vibrio parahaemolyticus virulence factors.

Authors:  Daniela Ceccarelli; Nur A Hasan; Anwar Huq; Rita R Colwell
Journal:  Front Cell Infect Microbiol       Date:  2013-12-11       Impact factor: 5.293

10.  Draft Genome Sequence of Cronobacter sakazakii Clonal Complex 45 Strain HPB5174, Isolated from a Powdered Infant Formula Facility in Ireland.

Authors:  Arthur W Pightling; Franco Pagotto
Journal:  Genome Announc       Date:  2014-08-07
View more
  5 in total

1.  A Nonautochthonous U.S. Strain of Vibrio parahaemolyticus Isolated from Chesapeake Bay Oysters Caused the Outbreak in Maryland in 2010.

Authors:  Julie Haendiges; Jessica Jones; Robert A Myers; Clifford S Mitchell; Erin Butler; Magaly Toro; Narjol Gonzalez-Escalona
Journal:  Appl Environ Microbiol       Date:  2016-05-16       Impact factor: 4.792

2.  Genomic Features of Environmental and Clinical Vibrio parahaemolyticus Isolates Lacking Recognized Virulence Factors Are Dissimilar.

Authors:  J Ronholm; N Petronella; C Chew Leung; A W Pightling; S K Banerjee
Journal:  Appl Environ Microbiol       Date:  2015-12-04       Impact factor: 4.792

3.  The mechanisms that regulate Vibrio parahaemolyticus virulence gene expression differ between pathotypes.

Authors:  Nicholas Petronella; Jennifer Ronholm
Journal:  Microb Genom       Date:  2018-05-29

4.  Engineering a customizable antibacterial T6SS-based platform in Vibrio natriegens.

Authors:  Biswanath Jana; Kinga Keppel; Dor Salomon
Journal:  EMBO Rep       Date:  2021-09-08       Impact factor: 8.807

5.  Transcriptional profiling of Vibrio parahaemolyticus exsA reveals a complex activation network for type III secretion.

Authors:  Aaron C Liu; Nikhil A Thomas
Journal:  Front Microbiol       Date:  2015-10-20       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.